Skip to content
Open access

Deep Learning-Based Multi-Cancer Analysis for Predicting Disease-Free Survival Across Multiple Cancer Types

Sep 2026 · Cancers · Vol 18 · 0 citations · 39 references
Medicine

TL;DR

The deep learning-based multi-cancer disease-free survival model performed robustly across cancer subtypes, with the nomogram improving risk stratification, particularly for stage I malignancies, complementing existing staging.

Abstract

Simple Summary Artificial intelligence-derived parameters hold promise for tumor prognosis, yet their application across cancer types remains underexplored. We developed a deep learning-based multi-cancer disease-free survival (MC-DFS) model using 8856 cases with whole-slide images and clinical data. The training cohort comprised 7392 cases from TCGA (24 cancer types), and independent external validation included 1464 cases from CPTAC and a hospital cohort (9 cancer types). Subsequently, a nomogram (NOMO) integrating MC-DFS, tumor stage, and age was constructed. In the training and validation cohorts, MC-DFS achieved AUCs of 0.750 and 0.682, respectively, with hazard ratios of 4.823 and 2.092 (both p < 0.0001). The model performed robustly across cancer subtypes, with the nomogram improving risk stratification, particularly for stage I malignancies, complementing existing staging. With multicenter validation, this system could become a practical tool for managing diverse cancers.

Read PDF

Similar papers

Open access Sep 2026

Predicting Tumor Mutational Burden in Prostate Cancer Using Deep Learning on Histopathological Images

It is suggested that deep learning models, particularly Inception V3, can effectively predict TMB status in patients using histopathological images, and the potential for integrating DL techniques in clinical settings to enhance personalized treatment strategies for patients with varying TMB is highlighted.

T. A. Serel, Onur Ertunç, M. Kıran et al. · 0 citations
Open access Sep 2026

Interpretable machine learning for individualized survival prediction in node-positive, non-metastatic prostate cancer: a population-based study.

The RSF model provides accurate, robust, and interpretable prognostication for N1M0 prostate cancer, and enables precise risk stratification and individualized treatment planning as a web-based calculator.

Er-Hao Bao, Y. Chai, Yang Yang et al. · 0 citations
#artificial intelligence Review Oct 2026

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

A two-stage AI model predicting pathological complete response to neoadjuvant therapy in breast cancer and transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays'gene selection constraints are developed.

Jungkyu Park, D. Biswas, J. Cappadona et al. · 0 citations

Cancer Survival Prediction through Multifactorial Analysis with Machine Learning

These results validate the feasibility of applying artificial intelligence to Brazilian hospital oncology records, demonstrating the potential of these models for future clinical decision-support applications within the Unified Health System (SUS).

I. Ribeiro, Rigue Luigi, Mello Rigato et al. · 0 citations
Open access Sep 2026

UMPM-Net: A Multimodal Deep Learning Framework for Colorectal Cancer Prognosis

The proposed UMPM-Net is a comprehensive, explainable and robust multimodal learning framework that is capable of accurate, interpretable, and clinically relevant prognostication for colorectal cancer.

K. Muthuchamy, S. K. Piramu Preethika · 0 citations
Conference

Deep Learning Pathomics for Predicting Clinical Outcomes in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with a five-year survival rate around 10%. Traditional prognostic methods, including imaging and blood markers like CA19-9, often fail to accurately predict therapeutic responses and outcomes. This research aims to enhance the prediction of disea...

Amol Shirodkar · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.